The enforcement timeline behind that suspension is detailed below: 2018 FDA Warning Letter after a 2017 inspection found serious deficiencies in sterile drug production that put patients at risk 2021 & 2023 Additional FDA Form 483s, with 2023 findings including no continuous cleanroom pressure monitoring, non-sterile wipes used in ISO 5 areas, and inadequate cross-contamination controls 2025 Pennsylvania fined Boothwyn $1 million for compounding ~30,000 GLP-1 doses in uninspected, unlicensed spaces, concealed from inspectors across four separate state inspections July 2025 Voluntary recall of compounded semaglutide 2.5 mg/mL (1,476 total vials across three sizes) due to subpotency January 2026 FDA Warning Letter citing sterility failures, subpotent semaglutide and tirzepatide formulations, and sterile products distributed before final sterility results were confirmed California Board of Pharmacy proceedings alleging eleven lots of compounded sterile preparations failed strength and purity requirements, and that an executive presented false and misleading documents to a state inspector Type of Pharmacy Boothwyn Pharmacy LLC is a 503A state-licensed compounding pharmacy

Stay Hydrated: Water Is Key Aim for 23 litres of water each day
doi: 10.1371/journal.pone.0171860 108 GattMEStrahilevitzJSharonNLavieDGoldschmidtNKalishYet al
Before you get that prescription, ask yourself: Am I willing to risk permanent, incurable complications for weight loss
By inhibiting the naturally occurring enzyme PDE4, which degrades cAMP, with the drug roflumilast they showed that they could skew neurons toward a sustained response
This often means that the control arm in RCTs is also subject to stricter, medication-based therapy